GlassScriptPhysician profile
Karen N Whitehead
NPI 1295037299
$2,368.90
in general payments reported to CMS, 2019-2025
19 companies · $471 in 2025
The $471 reported for 2025 was more than what a typical Adult Health (Nurse Practitioner) provider received nationally (typical 2025 total: $182).
See the full distribution for Adult Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $475 · 2023: $1,074 · 2024: $349 · 2025: $471.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,874 · Long Term Medical Supply Or Device Loan: $19.98.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,873.66 |
| Long Term Medical Supply Or Device Loan | $19.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $496.79 | 2022-2024 | Breztri, Farxiga, Airsupra |
| Glaxosmithkline, LLC. | $351.35 | 2022-2024 | Trelegy Ellipta, Shingrix, Arexvy |
| Lilly USA, LLC | $303.41 | 2023-2024 | Mounjaro, Jardiance, Emgality |
| Amgen INC. | $259.17 | 2023-2025 | Repatha, Repatha, Otezla |
| Novo Nordisk INC | $181.52 | 2022-2025 | Ozempic, Rybelsus |
| Mylan Specialty L.P. | $162.19 | 2023 | Yupelri, Yupelri |
| Abbott Laboratories | $128.22 | 2023-2025 | Freestyle Libre 2, Freestyle Libre 3, Freestyle Insulinx |
| Pfizer INC. | $98.29 | 2023-2025 | |
| Otsuka America Pharmaceutical, INC. | $97.50 | 2024-2025 | Rexulti, Abilify Asimtufii |
| Abbvie INC. | $49.15 | 2023-2025 | |
| Teva Pharmaceuticals USA, INC. | $48.01 | 2025 | Uzedy, Austedo Xr |
| Dexcom, INC. | $36.57 | 2025 | Dexcom G6 Transmitter |
| Exact Sciences Corporation | $31.82 | 2023-2024 | Cologuard Collection Kit |
| Idorsia Pharmaceuticals US INC | $26.18 | 2023 | Quviviq |
| Indivior INC. | $22.79 | 2025 | Sublocade |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eisai INC. | $21.21 | 2024 | |
| Neurocrine Biosciences, INC. | $19.17 | 2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $18.78 | 2022 | |
| Janssen Pharmaceuticals, INC | $16.78 | 2023 | Xarelto |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Karen Whitehead listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.